Goldman Sachs Group Inc. trimmed its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 22.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 217,550 shares of the biopharmaceutical company’s stock after selling 62,875 shares during the quarter. Goldman Sachs Group Inc. owned 0.17% of Celldex Therapeutics worth $537,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Voya Investment Management LLC lifted its holdings in shares of Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 7,499 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Celldex Therapeutics by 69.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 832,186 shares of the biopharmaceutical company’s stock worth $2,056,000 after buying an additional 339,639 shares during the period. Virtu KCG Holdings LLC raised its position in shares of Celldex Therapeutics by 458.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 117,770 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 96,687 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 7.8% in the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after acquiring an additional 708,095 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Celldex Therapeutics by 12.2% in the 2nd quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after acquiring an additional 219,661 shares in the last quarter. Institutional investors and hedge funds own 53.06% of the company’s stock.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) opened at $2.73 on Monday. Celldex Therapeutics, Inc. has a 1 year low of $2.20 and a 1 year high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. During the same period in the prior year, the company posted ($0.29) EPS. The firm’s quarterly revenue was up 77.3% compared to the same quarter last year. research analysts expect that Celldex Therapeutics, Inc. will post -0.97 EPS for the current year.

Several research firms have recently commented on CLDX. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. HC Wainwright reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Finally, BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Three analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.31.

ILLEGAL ACTIVITY WARNING: This report was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://theolympiareport.com/2017/11/13/goldman-sachs-group-inc-lowers-holdings-in-celldex-therapeutics-inc-cldx.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.